BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH
December 10, 2013 at 07:50 AM EST
BioLineRx (NASDAQ: BLRX ) announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show
